Regulatory T-cell receptor

Regulatory T-cell receptors refer to a diverse group of cell surface proteins expressed on regulatory T cells (Tregs) that are essential for maintaining immunological self-tolerance and modulating immune responses. This category includes the T-cell receptor (TCR) complex, which recognizes self-antigens, as well as various co-receptors and immune checkpoints such as CTLA-4, CD25 (IL-2 receptor alpha), GITR, OX40, LAG-3, and TIGIT. In the context of oncology, these receptors are targeted by monoclonal antibodies to deplete or inhibit the suppressive activity of Tregs within the tumor microenvironment, thereby promoting anti-tumor immunity. Conversely, in autoimmune diseases and transplantation, agonists or modulators of these receptors are investigated to enhance Treg function and restore immune balance. The therapeutic manipulation of these receptors is a cornerstone of modern immunotherapy, though it carries risks of systemic autoimmunity and immune-related adverse events. Drugs like ipilimumab target CTLA-4 to block its inhibitory signal, while others like daclizumab target CD25 to modulate IL-2 signaling. The specificity of the Treg TCR repertoire is also a subject of intense research for developing antigen-specific Treg therapies. Overall, these receptors serve as critical nodes for controlling the intensity and duration of immune reactions.

Other names

Treg receptorsRegulatory T-cell surface markersTreg-associated receptorsImmune checkpoint receptors on Tregs

Modulation of regulatory T cell activity through depletion, inhibition of suppressive function, or enhancement of Treg-mediated tolerance.